Eli Lilly and Company

Other

Robert D Dillard

Nicholas J Bach

Susan Elizabeth Draheim

Richard Walter Schevitz

Michael J Sofia

Edward David Mihelich

Tulio Suarez

J Scott Sawyer

Doris E McCullough

F Patrick Carr

Robert B Hermann

Jason Scott Sawyer

Daniel Jon Sall

Douglas Wade Beight

Mitsuaki Ohtani

John Michael Morin, Jr

Ho-Shen Lin

Jolie Anne Bastian

Michael Enrico Richett

Richard Waltz Harper

Michael LeRoy Phillips

Michael Dean Kinnick

Benjamin Alan Anderson

Robert Theodore Vasileff

Sanji Hagishita

Michael Lyle Denney

Nancy Kay Harn

Gary A Hite

John Mcneill McGill, Iii

Richard James Loncharich

Donald E Pavey

Winston S Marshall

Paul E Floreancig

S Richard Baker

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

A class of novel indolizine-1-functional compounds and indolizine-3-functional compounds is disclosed together with the use of such indolizine compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are indolizine-1-acetamides, indolizine-1-acetic acid hydrazides, indolizine-1-glyoxylamides, indolizine-3-acetamides, indolizine-3-acetic acid hydraxides, and indolizine-3-glyoxylasides.

Indolizine SPLA2inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Indole sPLA2 inhibitors

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA2 inhibitors

A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-acetamide sPLA2 inhibitors

Indene-1-acetamide compounds of the general formula (I) below;

Indene-1-acetamide sPLA2 inhibitors

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors

Process for preparing 1H-indole-3-glyoxylamides

A class of novel pyrroles is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

Pyrroles as sPLA.sub.2 inhibitors

A class of novel 1-indole-3-acetamides represented by the formula; ##STR1## is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids.

1H-indole-3-acetamide sPLA.sub.2 inhibitors

1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors

A class of novel 1H-indole-1-functional compounds is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides.

1H-indole-1-functional sPLA.sub.2 inhibitors

Growing community of inventors

Zionsville, IN, United States of America

Robert D Dillard